Drug Trial Radar · NCT06599658
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
660
Planned (sponsor's estimate)
Start
Nov 20, 2024
Primary completion
Jan 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centre hospitalier de l'Université de Montréal (CHUM)
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month after the initial COVID-19 booster and superior in the 3-month interval arms vs. the 6-month interval arms at 12 months after the initial COVID-19 booster. These outcomes will also be compared at 2-months for question 1 and 6-months for question 2. People living with immunocompromising conditions who take part in the trial will have blood samples drawn to verify immune response, be monitored for changes in clinical events and therapies, and complete questionnaires to verify adverse effects, quality of life and economic impact.
Conditions
- COVID 19
- Influenza
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erthematosus
- Inflammatory Bowel Disease
- Solid Organ Transplant Recipients
- Immunocompromised Host
- People Living With HIV
Interventions
Inactivated influenza vaccine (IIV) at baselineBiological
National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline
COVID-19 Vaccines at a 3-month intervalBiological
Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval
Inactivated influenza vaccine at Month 1Biological
National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster
COVID-19 Vaccines at a 6-month intervalBiological
Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median neutralization capacity against prevalent SARS-CoV-2 variantTime frame: At 1-month and 2-months following the initial COVID-19 booster dose for primary objective 1 and at 12-months and 6-months following initial COVID-19 booster dose for primary objective 2
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Maisonneuve -Rosemont Installation
Montreal, Quebec, Canada · Active not recruiting
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Recruiting
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.